Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 40

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Tetracyclines—An Important Therapeutic Tool for Dermatologists

Orylska-Ratynska, Malgorzata, Placek, Waldemar, Owczarczyk-Saczonek, Agnieszka · 2022 · International Journal of Environmental Research and Public Health

Published version of a preprint

Abstract

Tetracyclines are a group of antibiotics whose first representative was discovered over 70 years ago. Since then, they have been of great interest in dermatology. In addition to their antibacterial activity, they are able to inhibit metalloproteinases and exhibit anti-inflammatory, anti-apoptotic and antioxidant effects. The side effects have been thoroughly studied over the years, the most characteristic and important ones in daily dermatological practice being: phototoxicity, hyperpigmentation, onycholysis, photoonycholysis, induced lupus erythematosus, and idiopathic intracranial hypertension. In this article, we summarize the use of tetracyclines in infectious diseases and inflammatory dermatoses, and further discuss the instances where the efficacy and safety of tetracyclines have been highlighted over the past few years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijerph19127246

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 94

  1. Duggar, 1948, Aureomycin: A product of the continuing search for new antibiotics, Ann. N. Y. Acad. Sci., 51, 177, 10.1111/j.1749-6632.1948.tb27262.x · DOI · Paper page
  2. Ian, 2001, Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance, Microbiol. Mol. Biol. Rev., 65, 232, 10.1128/MMBR.65.2.232-260.2001 · DOI · Paper page
  3. Zakeri, 2008, Chemical biology of tetracycline antibiotics, Biochem. Cell Biol., 86, 124, 10.1139/O08-002 · DOI
  4. Nelson, 1998, Chemical and biological dynamics of tetracyclines, Adv. Dent. Res., 12, 5, 10.1177/08959374980120011901 · DOI
  5. Griffin, 2011, Tetracycline compounds with non-antimicrobial organ protective properties: Possible mechanisms of action, Pharmacol. Res., 63, 102, 10.1016/j.phrs.2010.10.004 · DOI · Paper page
  6. Golub, 1991, Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs, Crit. Rev. Oral Biol. Med., 2, 297, 10.1177/10454411910020030201 · DOI · Paper page
  7. Stephens, 1954, The structure of aureomycin, J. Am. Chem. Soc., 76, 3568, 10.1021/ja01642a064 · DOI
  8. Golub, 1992, Host modulation with tetracyclines and their chemically modified analogues, Curr. Opin. Dent., 2, 80
  9. Livermore, 1990, Antibiotic uptake and transport by bacteria, Scand J. Infect. Dis. Suppl., 74, 15
  10. White, 1982, Characterization of chlortetracycline (aureomycin) as a calcium ionophore, Biochemistry, 21, 6309, 10.1021/bi00267a041 · DOI
  11. Nelson, 1993, Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines, J. Med. Chem., 36, 370, 10.1021/jm00055a008 · DOI
  12. Ryan, 2001, Excessive matrix metalloproteinase activity in diabetes: Inhibition bytetracycline analogues with zinc reactivity, Curr. Med. Chem., 8, 305, 10.2174/0929867013373598 · DOI
  13. Stezowski, 1975, Chemical structural properties of tetracycline derivatives. 1. Molecular structure a Nd conformation of the free base derivatives, J. Am. Chem. Soc., 98, 6012, 10.1021/ja00435a039 · DOI
  14. Lambs, 1988, Metal ion-tetracycline interactions in biological fluids. Part 9. Circular dichroism spectra of calcium and magnesiumcomplexes with tetracycline, oxytetracycline, doxycycline and chlortetracycline, and and discussion of their binding modes, Inorg. Chem., 27, 3001, 10.1021/ic00290a022 · DOI
  15. Stezowski, 1977, Chemical-structural preperties of tetracycline derivatives. 3. The integrity of the conformation of the nonionized free base, J. Am. Chem. Soc., 99, 1117, 10.1021/ja00446a024 · DOI
  16. Alexey, 2006, The Tetracycline: Mg2+ Complex: A Molecular Mechanics force, Field. J. Comput. Chem., 27, 1517, 10.1002/jcc.20453 · DOI
  17. Guerra, 2016, Impact of metal coordination on the antibiotic and non-antibiotic activities of tetracycline-based drugs, Coord. Chem. Rev., 327–328, 188, 10.1016/j.ccr.2016.04.009 · DOI
  18. Webster, 2016, Status report from the scientific panel on antiobiotic use in dermatology of the American Acne and Rosacea Society:part 1: Antiobiotic prescribing patterns, sources of antibiotic exposure, antibiotic consumption and emergence of antibiotic resistance, impast of alterations in antibiotic prescribing, and clinical sequelae of antibiotic use, J. Clin. Aesthet. Dermatol., 9, 18
  19. Golub, 1998, Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms, Adv. Dent. Res., 12, 12, 10.1177/08959374980120010501 · DOI · Paper page
  20. Arvelo, 2006, Metalloproteinases in tumor progression, Review. Invest. Clin., 47, 185
  21. Roy, 2011, Jack of all trades: Pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS), Pharmacol. Res., 64, 580, 10.1016/j.phrs.2011.06.012 · doi:10.1016/j.phrs.2011.06.012
  22. Khanapure, 2007, Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers, Curr. Top. Med. Chem., 7, 311, 10.2174/156802607779941314 · DOI · Paper page
  23. Bahrami, 2012, Tetracyclines: Drugs with huge therapeutic potential, Mini Rev. Med. Chem., 12, 44, 10.2174/138955712798868977 · DOI
  24. Webster, 2007, Anti-inflammatory activity of tetracyclines, Dermatol. Clin., 25, 133, 10.1016/j.det.2007.01.012 · DOI
  25. Goodheart, 1979, Further evidence of the role of bivalent cations in leukocyte chemotaxis, J. Reticuloendothel. Soc., 25, 545
  26. Trachtman, 1996, Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells, Biochem. Biophys. Res. Commun., 229, 243, 10.1006/bbrc.1996.1787 · doi:10.1006/bbrc.1996.1787
  27. Griffin, 2010, Tetracyclines: A pleitropic family of compounds with promising therapeutic properties. Review of the literature, Am. J. Physiol., 299, C539, 10.1152/ajpcell.00047.2010 · DOI · Paper page
  28. Kraus, 2005, Antioxidant properties of minocycline: Neuroprotectionin an oxidative stress assay and direct radical-scavenging activity, J. Neurochem., 94, 819, 10.1111/j.1471-4159.2005.03219.x · DOI · Paper page
  29. Cryns, 1998, Proteases to die for [published correction appears in Genes Dev 1999 Feb 1;13:371], Genes Dev., 12, 1551, 10.1101/gad.12.11.1551 · DOI · Paper page
  30. Sagar, 2010, Doxycycline in mitochondrial mediated pathway of apoptosis: A systematic review, Anti-Cancer Agents Med. Chem., 10, 556, 10.2174/187152010793498645 · doi:10.2174/187152010793498645
  31. Vucic, 2012, The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy, Exp. Oncol., 34, 200
  32. Garrido, 2006, Mechanisms of cytochrome c release from mitochondria, Cell Death Differ., 13, 1423, 10.1038/sj.cdd.4401950 · DOI · Paper page
  33. Susin, 1999, Molecular characterization of mitochondrial apoptosis-inducing factor, Nature, 397, 441, 10.1038/17135 · DOI · Paper page
  34. Joza, 2001, Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death, Nature, 410, 549, 10.1038/35069004 · DOI · Paper page
  35. Chen, 2000, Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease, Nat. Med., 6, 797, 10.1038/77528 · DOI · Paper page
  36. Riesbeck, 1990, Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob, Agents Chemother., 34, 167, 10.1128/AAC.34.1.167 · DOI
  37. Desco, 2021, Minocycline in neurodegenerative and psychiatric diseases: An update, Eur. J. Neurol., 28, 1056, 10.1111/ene.14642 · DOI
  38. Barza, 1975, Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs, Antimicrob Agents Chemother., 8, 713, 10.1128/AAC.8.6.713 · DOI · Paper page
  39. Thiboutot, 2009, New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group, J. Am. Acad. Dermatol., 60, 1, 10.1016/j.jaad.2009.01.019 · DOI · Paper page
  40. Di Caprio, R., Lembo, S., Di Costanzo, L., Balato, A., and Monfrecola, G. (2015). Anti-inflammatory properties of low and high doxycycline doses: An in vitro study. Mediators Inflamm., 329418. · DOI
  41. Sorsa, 2006, Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation, Ann. Med., 38, 306, 10.1080/07853890600800103 · DOI · Paper page
  42. 2017, Third time lucky? Getting a grip on matrix metalloproteinases, J. Biol. Chem., 292, 17975, 10.1074/jbc.H117.806075 · doi:10.1074/jbc.h117.806075
  43. Hoyt, 2006, Doxycycline modulates nitric oxide production in murine lung epithelial cells, J. Immunol., 176, 567, 10.4049/jimmunol.176.1.567 · DOI
  44. Cunliffe, 2003, Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle, J. Am. Acad. Dermatol., 49, 218, 10.1067/S0190-9622(03)01153-8 · DOI
  45. Chen, 2020, Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2, Pharmacol. Res., 159, 105007, 10.1016/j.phrs.2020.105007 · DOI
  46. Maglie, 2019, Impressive response of erosive pustular dermatosis of the scalp to lymecycline monotherapy, J. Dtsch. Dermatol. Ges., 17, 1177
  47. Bossuyt, 2003, Lymecycline in the treatment of acne: An efficacious, safe and cost-effective alternative to minocycline, Eur. J. Dermatol., 13, 130
  48. Grosshans, 1998, A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris, Eur. J. Dermatol., 8, 161
  49. Berber, 2014, Safety and efficacy comparison of minocycline microgranules vs lymecycline in the treatment of mild to moderate acne: Randomized, evaluator-blinded, parallel, and prospective clinical trial for 8 weeks, J. Drugs Dermatol., 13, 671
  50. Zhanel, 2004, The glycylcyclines: A comparative review with the tetracyclines, Drugs, 64, 63, 10.2165/00003495-200464010-00005 · DOI · Paper page
  51. Zhanel, 2018, Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris, Antimicrob. Agents Chemother., 21, e01297-18
  52. Kaul, 2019, Sarecycline hydrochloride for the treatment of acne vulgaris, Drugs Today, 55, 615, 10.1358/dot.2019.55.10.3045040 · doi:10.1358/dot.2019.55.10.3045040
  53. Lee, A., and Thomson, J. (2006). Drug-Induced Skin Reactions, Pharmaceutical Press. [2nd ed.].
  54. Odorici, 2021, Tetracyclines and photosensitive skin reactions: A narrative review, Dermatol. Ther., 34, e14978, 10.1111/dth.14978 · DOI
  55. Gordon, 1985, Hiperpigmentation of the Skin Associated With Minocycline Therapy, Arch. Dermatol., 121, 618, 10.1001/archderm.1985.01660050070017 · doi:10.1001/archderm.1985.01660050070017
  56. Abdelghany, 2016, Minocycline-induced hyperpigmentation, Cleve Clin. J. Med., 83, 876, 10.3949/ccjm.83a.16058 · doi:10.3949/ccjm.83a.16058
  57. Wlodek, 2014, A reminder about photo-onycholysis induced by tetracycline, and the first report of a case induced by lymecycline, Clin. Exp. Dermatol., 39, 746, 10.1111/ced.12350 · DOI
  58. Czap, 2020, Distal Phototoxic Onycholysis, Dtsch Arztebl Int., 20, 196
  59. Tan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 25, 1271, 10.1002/art.1780251101 · DOI · Paper page
  60. Schlienger, 2000, Minocycline-Induced Lupus, Dermatology, 200, 223, 10.1159/000018387 · DOI
  61. Wall, 2017, Update on Idiopathic Intracranial Hypertension, Neurol. Clin., 35, 45, 10.1016/j.ncl.2016.08.004 · DOI
  62. Tan, 2020, Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes, Am J Clin Dermatol., 21, 163, 10.1007/s40257-019-00485-z · doi:10.1007/s40257-019-00485-z
  63. Bababeygy, S.R., Repka, M.X., and Subramanian, P.S. (2009). Minocycline-associated pseudotumor cerebri with severe papilledema. J. Ophthalmol., 203583. · doi:10.1155/2009/203583
  64. Warner, 2002, Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension, Ann. Neurol., 52, 647, 10.1002/ana.10377 · doi:10.1002/ana.10377
  65. Lantos, 2021, Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease, Arthritis Rheumatol., 73, 12, 10.1002/art.41562 · DOI
  66. Janier, 2021, 2020 European guideline on the management of syphilis, J. Eur. Acad. Dermatol. Venereol., 35, 574, 10.1111/jdv.16946 · DOI · Paper page
  67. Lanjouw, 2016, European guideline on the management of Chlamydia trachomatis infections, Int. J. STD Aids, 27, 333, 10.1177/0956462415618837 · DOI · Paper page
  68. 2019, European guideline on the management of lymphogranuloma venereum, J Eur. Acad. Dermatol. Venereol., 33, 1821, 10.1111/jdv.15729 · DOI
  69. Moi, 2016, European guideline on donovanosis, Int. J. STD Aids, 27, 605, 10.1177/0956462416633626 · doi:10.1177/0956462416633626
  70. Fralish, 2020, African Tick-Bite Fever, Am. J. Med., 133, 1051, 10.1016/j.amjmed.2020.03.031 · doi:10.1016/j.amjmed.2020.03.031
  71. Karachitos, 2010, Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells, Biochemistry, 79, 239
  72. Sapadin, 2006, Tetracyclines: Nonantibiotic properties and their clinical implications, J. Am. Acad. Dermatol., 54, 258, 10.1016/j.jaad.2005.10.004 · DOI · Paper page
  73. Zaenglein, 2016, Guidelines of care for the management of acne vulgaris, J. Am. Acad. Dermatol., 74, 945, 10.1016/j.jaad.2015.12.037 · DOI · Paper page
  74. Amin, 1997, Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines, FEBS Lett., 410, 259, 10.1016/S0014-5793(97)00605-4 · DOI
  75. Monk, 2011, Clinical applications of nonantimicrobial tetracyclines in dermatology, Pharm. Res., 63, 130, 10.1016/j.phrs.2010.10.007 · DOI
  76. Joshi, 1993, Successful treatment of Sweet’s syndrome with doxycycline, Br. J. Dermatol., 128, 584, 10.1111/j.1365-2133.1993.tb00242.x · DOI
  77. Tan, 1989, The successful use of minocycline in pyoderma gangrenosum—A report of seven cases and review of the literature, J. Dermatol. Treatment, 1, 23, 10.3109/09546638909086683 · DOI
  78. Webster, 1994, Inhibition of in vitro granuloma formation by tetracyclines and ciprofloxacin: Involvement of protein kinase C, Arch. Dermatol., 130, 748, 10.1001/archderm.1994.01690060078008 · DOI
  79. Peterson, 2004, Matrix metalloproteinase inhibitor development and the remodeling of drug discovery, Heart Fail. Rev., 9, 63, 10.1023/B:HREV.0000011395.11179.af · DOI · Paper page
  80. Kennedy, 2014, Tetracycline: A cure all?, Br. J. Oral Maxillofac. Surg., 52, 382, 10.1016/j.bjoms.2014.01.020 · doi:10.1016/j.bjoms.2014.01.020
  81. Marsland, 2001, Treatments for chronic palmoplantar pustular psoriasis, Ski. Ther. Lett., 6, 3
  82. Gulliver, 2016, Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa, Rev. Endocr. Metab. Disord., 17, 343, 10.1007/s11154-016-9328-5 · DOI · Paper page
  83. Blevins, M. (2021). Atypical Ulcerative Necrobiosis Lipoidica Diabeticorum: A Case Study. Int. J. Low. Extrem. Wounds. · DOI
  84. Duarte, 2009, Generalized granuloma annulare—Response to doxycycline, J. Eur. Acad. Dermatol. Venereol., 23, 84, 10.1111/j.1468-3083.2008.02707.x · doi:10.1111/j.1468-3083.2008.02707.x
  85. Burns, 2020, Necrobiosis lipoidica with rapid response to doxycycline, Pediatr. Dermatol., 37, 981, 10.1111/pde.14295 · DOI
  86. Mumford, 2021, Prurigo pigmentosa: The “keto rash”, Med. J. Aust., 2, 108, 10.5694/mja2.51162 · doi:10.5694/mja2.51162
  87. Nagashima, 1978, Prurigo pigmentosa-clinical observations of our 14 cases, J. Dermatol., 5, 61, 10.1111/j.1346-8138.1978.tb01049.x · doi:10.1111/j.1346-8138.1978.tb01049.x
  88. Lu, 2022, Keto Rash: Ketoacidosis-Induced Prurigo Pigmentosa, Mayo Clin. Proc., 97, 20, 10.1016/j.mayocp.2021.11.019 · doi:10.1016/j.mayocp.2021.11.019
  89. Kurzen, 2008, What causes hidradenitis suppurativa?, Exp. Dermatol., 17, 455, 10.1111/j.1600-0625.2008.00712_1.x · DOI · Paper page
  90. Yu, 1990, Hidradenitis suppurativa: A disease of follicular epithelium, rather than apocrine glands, Br. J. Dermatol., 122, 763, 10.1111/j.1365-2133.1990.tb06264.x · DOI · Paper page
  91. Jemec, 1996, Histology of hidradenitis suppurativa, J. Am. Acad. Dermatol., 34, 994, 10.1016/S0190-9622(96)90277-7 · DOI · Paper page
  92. Kamp, 2011, Hidradenitis suppurativa: A disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa, Br. J. Dermatol., 164, 1017, 10.1111/j.1365-2133.2011.10224.x · DOI
  93. Albrecht, 2019, Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic, Br. J. Dermatol., 180, 749, 10.1111/bjd.17265 · doi:10.1111/bjd.17265
  94. Tzellos, 2021, The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study, J. Am. Acad. Dermatol., 85, 369, 10.1016/j.jaad.2020.12.089 · doi:10.1016/j.jaad.2020.12.089

Cited by

See all 40

Metadata

Authors
Orylska-Ratynska, M., Placek, W., & Owczarczyk-Saczonek, A.
Affiliations
Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury in Olsztyn, Oczapowskiego 2, 10-719 Olsztyn, Poland
Venue
International Journal of Environmental Research and Public Health
Publisher
MDPI AG
Published
2022-06-13
Volume
19
Issue
12
Pages
7246
ISSN
1660-4601
Cited by
40
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.